Critical review of dose-response options for F344 rat mammary tumors for acrylamide - Additional insights based on mode of action

Food and Chemical Toxicology

Volumn 50, Issue 5, 2012, Pages 1763-1775

  Maier, Andrew ^a   Kohrman Vincent, Melissa ^a   Hertzberg, Richard ^b   Allen, Bruce ^c   Haber, Lynne T ^a   Dourson, Michael ^a  

^a Toxicology Excellence for Risk Assessment   (United States)

^b EMORY UNIVERSITY   (United States)

^c GBA Associates   (United States)

Author keywords

Acrylamide; Dose response; Mammary tumor; Mode of action analysis; Risk assessment

Indexed keywords

ACRYLAMIDE; DNA; GLYCIDAMIDE;

ARTICLE; BREAST ADENOCARCINOMA; BREAST ADENOMA; BREAST CARCINOGENESIS; BREAST FIBROADENOMA; BREAST FIBROMA; BREAST HYPERPLASIA; BREAST TUMOR; CANCER GROWTH; CELL INTERACTION; EPIGENETICS; EPITHELIUM CELL; GENOTOXICITY; HYPERPROLACTINEMIA; MUTAGENICITY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; RAT; STROMA CELL;

ACRYLAMIDE; ANIMALS; CARCINOGENS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; RATS; RATS, INBRED F344;

ANIMALIA; RATTUS;

EID: 84859880548     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.02.002     Document Type: Article

References (74)

1. Ali S., Jau-Shyong H., Wilson W.E., Uphouse L.L., Bondy S.C. Effect of acrylamide on neurotransmitter metabolism and neuropeptide levels in several brain regions and upon circulating hormones. Arch. Toxicol. 1983, 52:35-43.
2. Barcellos-Hoff M., Medina D. New highlights on stroma-epithelial interactions in breast cancer. Breast Cancer Res. 2005, 7:33-36.
3. Boobis A.R., Cohen S.M., Dellarco V., McGregor D., Meek M.E., Vickers C., Willcocks D., Farland W. IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit. Rev. Toxicol. 2006, 36:781-792.
4. Bowyer, J.F., Latendresse, J.R., Delongchamp, R.R., Muskhelishvili, L., Warbritton, A.R., Thomas, M., Tareke, E., McDaniel, L.P., Doerge, D.R., in press. The effects of subchronic acrylamide exposure on gene expression, neurochemistry, hormones, and histopathology in the hypothalamus-pituitary-thyroid axis of male Fischer 344 rats. Toxicol. Appl. Pharmacol.
5. Bull R., Robinson M., Laurie R.D., Stoner G.D., Greisiger E., Meier J.R., Stober J. Carcinogenic effects of acrylamide in Sencar and A/J mice. Cancer Res. 1984, 44:107-111.
6. Bull R., Robinson M., Stober J.A. Carcinogenic activity of acrylamide in the skin and lung of Swiss-ICR mice. Cancer Lett. 1984, 24:209-212.
7. Butterworth B.E., Eldridge S.R., Sprankle C.S., Working P.K., Bentley K.S., Hurtt M.E. Tissue-specific genotoxic effects of acrylamide and acrylonitrile. Environ. Mol. Mutagen. 1992, 20:148-155.
8. Carter C., Corle D.K., Micozzi M.S., Schatzkin A., Taylor P.R. A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am. J. Epidem. 1988, 128:467-477.
9. Carty N., Ravichandran D., Carter C., Royle G.T., Rubin C., Taylor I. Management of fibroadenoma of the breast. Ann. R. Coll. Surg. Engl. 1995, 77:127-130.
10. Chico Galdo V., Massart C., Jin L., Vanvooren V., Caillet-Fauquet P., Andry G., Lothaire P., Dequanter D., Friedman M., Van Sande J. Acrylamide, an in vivo thyroid carcinogenic agent, induces DNA damage in rat thyroid cell lines and primary cultures. Mol. Cell. Endocrinol. 2006, 257-258:6-14.
11. Ciatto S., Bonardi R., Zappa M., Giorgi D. Risk of breast cancer subsequent to histological or clinical diagnosis of fibroadenoma - retrospective longitudinal study of 3938 cases. Ann. Oncol. 1997, 8:297-300.
12. Dearfield K.L., Abernathy C.O., Ottley M.S., Brantner J.H., Hayes P.F. Acrylamide: its metabolism, developmental and reproductive effects, genotoxicity, and carcinogenicity. Mutat. Res. 1988, 195(1):45-77.
13. Dearfield K.L., Douglas G.R., Ehling U.H., Moore M.M., Sega G.A., Brusick D.J. Acrylamide: a review of its genotoxicity and an assessment of heritable genetic risk. Mutat. Res. 1995, 330(1-2):71-99.
14. Doerge D.R., da Costa G.G., McDaniel L.P., Churchwell M.I., Twaddle N.C., Beland F.A. DNA adducts derived from administration of acrylamide and glycidamide to mice and rats. Mutat. Res. 2005, 580:131-141.
15. Dourson M., Hertzberg R., Allen B., Haber L., Parker A., Kroner O., Maier A., Kohrman M.J. Evidence-based dose response assessment for thyroid tumorigenesis from acrylamide via oral exposure. Reg. Toxicol. Pharmacol. 2008, 52(3):264-289.
16. Dulak, 1989. A Lifetime oncogenicity study in rats with acrylamide. American Cyanamid Company, (unpublished version of Friedman et al., 1995), Study No. 85033.
17. Dupont W., Page D.L., Parl F.F., Vnencak-Jones C.L., Plummer W.D., Rados M.S., Schuyler P.A. Long-term risk of breast cancer in women with fibroadenoma. New Eng. J. Med. 1994, 331:10-15.
18. European Union, 2002. Risk Assessment Report. Acrylamide. European Chemicals Bureau, Institute for Health and Consumer Protection.
19. Franco N., Arnould L., Mege F., Picard S.-F., Arveux P., Lizard-Nacol S. Comparative analysis of molecular alterations in fibroadenomas associated or not with breast cancer. Arch. Surg. 2003, 138:291-295.
20. Friedman, M.A., Dulak, L.H., Keefe, R.T., 1999. Effects of acrylamide on rat hormone levels in a 28-day drinking water study. Exxon Biomedical Sciences, Inc.
21. Friedman M.A., Dulak L.H., Stedham M.A. A lifetime oncogenicity study in rats with acrylamide. Fundam. Appl. Toxicol. 1995, 27:95-105.
22. Gargas M.L., Kirman C.R., Sweeney L.M., Tardiff R.G. Acrylamide: consideration of species differences and nonlinear processes in estimating risk and safety for human ingestion. Food Chem. Toxicol. 2009, 47:760-768.
23. Haber L.T., Maier A., Kohrman M., Kroner O. Evidence-based assessment of human relevance and mode of action for tunica vaginalis mesotheliomas resulting from oral exposure to acrylamide. Reg. Toxicol. Pharmacol. 2009, 53:134-149.
24. Hartmann L., Sellers T.A., Frost M.H., Lingle W.L., Degnim A.C., Ghosh K., Vierkant R.A., Maloney S.D., Pankratz Z.S., Hillman D.W., Suman V.J., Johnson J., Blake C., Tjsty T., Vachon C.M., Meltson L.J., Visscher D.W. Benign breast disease and the risk of breast cancer. New Eng. J. Med. 2005, 353:229-237.
25. Harvey P. Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: prolactin involvement in human breast cancer and significance for toxicology risk assessments. J. Appl. Toxicol. 2005, 25:179-183.
26. Hogervorst J., Schouten L.J., Konings E.J., Goldbohm R.A., van den Brandt P.A. A prospective study of dietary acrylamide intake and the risk of endometrial, ovarian, and breast cancer. Cancer Epidemiol. Biomarkers Prev. 2007, 16(11):2304-2313.
27. Imai T., Cho Y.-M., Hasumura M., Hirose M. Enhancement by acrylamide of N-methyl-N-nitrosourea-induced rat mammary tumor development-possible application for a model to detect co-modifiers of carcinogenesis. Cancer Lett. 2005, 230:25-32.
28. Johnson K.A., Gorzinski S.J., Bodner K.M., Campbell R.A., Wolf C.H., Friedman M.A., Mast R.W. Chronic toxicity and oncogenicity study on acrylamide incorporated in the drinking water of Fischer 344 rats. Toxicol. Appl. Pharmacol. 1986, 85:154-168.
29. Johnson, K.A., Gorzinski, S.J., Bodner, K.M., Campbell, R.A., 1984. Acrylamide: a two-year drinking water chronic toxicity-oncogenicity study in Fischer 344 rats. Dow Chemical. Midland, MI. Unpublished Report.
30. K.S. Crump Group, Inc., 1999. Mechanism of acrylamide induction of benign mammary fibroadenomas in the aging female fischer 344 rat: relevance to human health risk assessment. K.S. Crump Group, Inc. Prepared for AMPA and PPG. December 14, 1999, pp. 1-33.
31. Khan M.A., Davis C.A., Foley G.L., Friedman M.A., Hansen L.G. Changes in thyroid gland morphology after acute acrylamide exposure. Toxicol. Sci. 1999, 47:151-157.
32. Kim J., Stein R., O'Hare M.J. Tumour-stromal interactions in breast cancer: the role of stroma in tumourigenesis. Tumor Biol. 2005, 26:173-185.
33. Klaunig J., Kamendulis L. Mechanisms of acrylamide induced rodent carcinogenesis. Chemistry and Safety of Acrylamide in Food 2005, 49-62. Springer Science & Business Media, Inc. Friedman, Mottram (Eds.).
34. Koyama N., Sakamoto H., Sakuraba M., Koizumi T., Takashima Y., Hayashi M., Matsufujii H., Yamagata K., Masuda S., Kinae N., Honma M. Genotoxicity of acrylamide and glycidamide in human lymphoblastoid TK6 cells. Mutat. Res. 2006, 603:151-158.
35. Kuijper A., Buerger H., Simon R., Schaefer K.-L., Croonen A., Boecker W., van der Wall E., van Diest P.J. Analysis of the progression of fibroepithelial tumours of the breast by PCR-based clonality assay. J. Pathol. 2002, 197:575-581.
36. Larsson S.C., Akesson A., Wolk A. Long-term dietary acrylamide intake and breast cancer risk in a prospective cohort of Swedish women. Am. J. Epidemiol. 2009, 169:376-381.
37. LoPachin R.M., Schwarcz A.I., Gaughan C.L., Mansukhani S., Das S. In vivo and in vitro effects of acrylamide on synaptosomal neurotransmitter uptake and release. NeuroToxicology 2004, 25:349-363.
38. LoPachin R., Barber D.S., He D., Das S. Acrylamide inhibits dopamine uptake in rat striatal synaptic vesicles. Toxicol. Sci. 2006, 89:224-234.
39. LoPachin R.M., Gavin T., Geohagen B.C., Das S. Neurotoxic mechanisms of electrophilic type-2 alkenes: soft soft interactions described by quantum mechanical parameters. Toxicol. Sci. 2007, 98(2):561-570.
40. Maffini M., Soto A.M., Calabro J.M., Ucci A.A., Sonnenschein C. The stroma as a crucial target in rat mammary gland carcinogenesis. J. Cell Sci. 2004, 117:1495-1502.
41. Markopoulos C., Kouskos E., Mantas D., Kontzoglou K., Antonopoulou Z., Revenas K., Kyriakou V. Fibroadenomas of the breast: is there any association with breast cancer?. Eur. J. Gynacc. Oncol. 2004, 25:495-497.
42. Marsh G.M., Youk A.O., Buchanich J.M., Kant I.J., Swaen G. Mortality patterns among workers exposed to acrylamide: updated follow up. J. Occup. Environ. Med. 2007, 49:82-95.
43. Marxfeld H., Staedtler F., Harleman J.H. Gene expression in fibroadenomas of the rat mammary gland in contrast to spontaneous adenocarcinomas and normal mammary gland. Experiment. Toxicol. Pathol. 2006, 58:145-150.
44. McConnell E.E., Soileveid M.A., Swenberg J.A., Boorman G.A. Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies. JNCL 1986, 76(2):283-293.
45. Mei N., Hu J., Churchwell M.I., Guo L., Moore M.M., Doerge D.R., Chen T. Genotoxic effects of acrylamide and glycidamide in mouse lymphoma cells. Food Chem. Toxicol. 2008, 46:628-636.
46. Meek M., Bucher J., Cohen S., Dellarco V., Hill R., Lehman-McKeeman L., Longfellow D., Pastoor T., Seed J., Patton D. A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol. 2003, 33:591-653.
47. Mucci L.A., Dickman P.W., Steineck G., Adami H.-O., Augustsson K. Dietary acrylamide and cancer of the large bowel, kidney, and bladder: absence of an association in a population-based study in Sweden. Br. J. Cancer 2003, 88:84-89.
48. Mucci L.A., Lindblad P., Steinbeck G., Adami H.-O. Dietary acrylamide and risk of renal cell cancer. Int. J. Cancer 2004, 109:774-776.
49. Mucci L.A., Sandin S., Magnusson C., Weiderpass E. Acrylamide intake and breast cancer risk in Swedish women. J. Am. Med. Assoc. 2005, 293(11):1326-1327.
50. Mucci L.A., Adami H.-O., Wolk A. Prospective study of dietary acrylamide and risk of colorectal cancer among women. Int. J. Cancer 2006, 118:169-173.
51. NTP (National Toxicology Program), 2011. Draft technical report on the toxicology and carcinogenesis studies of acrylamide (CAS No. 79-06-1) in F344/N rats and B6C3F1 mice (drinking water study). NTP TR 575. NIH Publication No. 11-5917.
52. OEHHA (Office of Environmental Health and Hazard Assessment), 2005. No significant risk level (NSRL) for the proposition 65 carcinogen acrylamide. Office of Environmental Health Hazard Assessment, California Environmental Protection Agency, Oakland, California.
53. Olesen P.T., Olsen A., Frandsend H., Fredericksen K., Overvad K., Tjonneland A. Acrylamide exposure and incidence of breast cancer among postmenopausal women in the Dansih diet, cancer and health study. Int. J. Cancer 2008, 122:2094-2100.
54. Park J., Kamendulis L.M., Friedman M.A., Klaunig J.E. Acrylamide-induced cellular transformation. Toxicol. Sci. 2002, 65:177-183.
55. Pelucchi C., Galeone C., Levi F., Negri E., Franceschi S., Talamini R., Bosetti C., Giacosa A., La Vecchia C. Dietary acrylamide and human cancer. Int. J. Cancer 2006, 118:467-471.
56. Puppel N., Tjaden Z., Fueller F., Marko D. DNA strand breaking capacity of acrylamide and glycidamide in mammalian cells. Mutat. Res. 2005, 580:71-80.
57. Rizou H., Bardi G., Arnaourti M., Apostolikas N., Sfikas K., Charlaftis A., Polichronis A., Agnantis N.J., Pandis N. Metaphase and interphase cytogenetics in fibroadenomas of the breast. In Vivo 2004, 18:703-712.
58. Robinson, M., Bull, R.J., Knutsen, G.L., Sheilds, R.P., Stober, J., 1986. A combined carcinogen bioassay utilizing both the lung adenoma and skin papilloma protocols. Environ. Health Perspect. 68, 141-145.
59. Rudel R.A., Attfield K.R., Schifano J.N., Brody J.G. Chemicals causing mammary gland tumors in animals signal new directions for epidemiology, chemicals testing, and risk assessment for breast cancer prevention. Cancer 2007, 109(12):2635-2666.
60. Russo I., Russo J. Mammary gland neoplasia in long-term rodent studies. Environ. Health Perspect. 1996, 104:938-962.
61. Shipp A., Lawrence G., Gentry R., McDonald T., Bartow H., Bounds J., Macdonald N., Clewell H., Allen B., Van Landingham C. Acrylamide: review of toxicity data and dose-response analyses for cancer and noncancer effects. Crit. Rev. Toxicol. 2006, 36:481-608.
62. Sickles D.W. Toxic neurofilamentous axonopathies and fast anterograde axonal transport. III. Recovery from single injections and multiple dosing effects of acrylamide and 2,5-hexanedione. Toxicol. Appl. Pharmacol. 1991, 108:390-396.
63. Sickles D.W., Stone J.D., Friedman M.A. Fast axonal transport: a site of acrylamide neurotoxicity?. NeuroToxicology 2002, 23:223-251.
64. Sonich-Mullin C., Fielder R., Wiltse J., Baetcke K., Dempsey J., Fenner-Crisp P., Grant D., Hartley M., Knaap A., Kroese D., Mangelsdorf I., Meek E., Rice J.M., Younes M. IPCS conceptual framework for evaluating a mode of action for chemical carcinogensis. Regul. Toxicol. Pharmacol. 2001, 34:146-152.
65. Swaen, G.M.H., Haidar, S., Burns, C.J., Bodner, K., Parsons, T., Collins, J.J., Baase, C., 2007. Mortality study update of acrylamide workers. J. Occup. Environ. Med. 64, 396-401.
66. Swenberg J.A., Haidar S., Burns C.J., Bodner K., Parsons T., Collins J.J., Baase C. Biomarkers in toxicology and risk assessment: informing critical dose response assessment relationships. Chem. Res. Toxicol. 2007, 21(1):253-265.
67. Tsai K., Chuang E.Y.-Y., Little J.B., Yuan Z.-M. Cellular mechanisms for low-dose ionizing radiation-induced perturbation of the breast tissue microenvironment. Cancer Res. 2005, 65:6374-6744.
68. Twaddle N.C., Churchwell M.I., McDaniel L.P., Doerge D.R. Autoclave sterilization produces acrylamide in rodent diets: implications for toxicitytesting. J. Agric. Food Chem. 2004, 52:4344-4349.
69. U.S. EPA (United States Environmental Protection Agency), 2011a. Integrated Risk Information System (IRIS); multiple chemical entries. Available from: http://www.epa.gov/iris.
70. U.S. EPA (United States Environmental Protection Agency), 2011b. Integrated Risk Information System (IRIS) for acrylamide. Available from: http://www.epa.gov/iris.
71. U.S. EPA (United States Environmental Protection Agency), 2009. Benchmark Dose Software Version 2.1.1. Available from: http://www.epa.gov/ncea/bmds/progreg.html.
72. U.S. EPA (United States Environmental Protection Agency), 2005. Guidelines for carcinogen risk assessment. United States Environmental Protection Agency EPA/630/P-03/001b.
73. Wilson K.M., Mucci L.A., Cho E., Hunter D.J., Chen W.Y., Willett W.C. Dietary acrylamide intake and risk of premenopausal breast cancer. Am. J. Epidemiol. 2009, 169:954-961.
74. Wiseman B.S., Werb Z. Stromal effects on mammary gland development and breast cancer. Science 2002, 296:1046-1049.